Half the Price, Same Business: What Zoetis’s Filed Numbers Actually Say
Two years ago, Zoetis traded at roughly 35 times its annual earnings. Today it trades at roughly 12 times. The...
Biogen: The Stock That Priced In a Recovery the Margins Haven’t Filed Yet
Five years ago, Biogen's stock briefly traded above $425 on the back of an Alzheimer's drug that Medicare ultimately refused...
Who Holds the IOU Holds the Vote
Foreign governments and central banks held about $4.69 trillion in U.S. Treasury bonds as of January 2026, according to the...
BioMarin: A Company Getting Bigger and Cheaper at the Same Time
The story, briefly BioMarin's filed numbers show a business that has grown revenue by more than half over the past...
Evidence Sheet: ExxonMobil Holdings (XOM)
The standing BullScope yardsticks for ExxonMobil Holdings, computed from official filings and refreshed with each new edition.
ExxonMobil: A Machine That Prints Cash While the Market Argues About the Price Tag
The heart of it ExxonMobil's filed numbers show a company generating more free cash in a single quarter than most...
Evidence Sheet: Home Depot (HD)
The standing BullScope yardsticks for Home Depot, computed from official filings and refreshed with each new edition.
Elanco Is Earning More Than It Ever Has. The Stock Is Priced Like That’s Just the Beginning.
The quick read Elanco's filed numbers show a business that spent five years losing money and is now generating real...
Growing and Stuck: The Economy Is Doing Two Things at Once
For the past year and a half, the Federal Reserve has been trying to cool prices without tipping the economy...
Evidence Sheet: Vertex Pharmaceuticals Inc / Ma (VRTX)
The standing BullScope yardsticks for Vertex Pharmaceuticals Inc / Ma, computed from official filings and refreshed with each new edition.
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.